Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Left-sided heart disease and risk of death in patients with end-stage kidney disease receiving haemodialysis: an observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pulmonary artery pressure as a method for assessing hydration status in an anuric hemodialysis patient - a case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiac function assessed by myocardial deformation in adult polycystic kidney disease patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The impact of hemodialysis on mortality risk and cause of death in Staphylococcus aureus endocarditis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Dimitrios Chanouzas
  • Julie Anne G McGregor
  • Peter Nightingale
  • Alan D Salama
  • Wladimir M Szpirt
  • Neil Basu
  • Matthew David Morgan
  • Caroline J Poulton
  • Juliana Bordignon Draibe
  • Elizabeth Krarup
  • Paula Dospinescu
  • Jessica Anne Dale
  • William Franklin Pendergraft
  • Keegan Lee
  • Martin Egfjord
  • Susan L Hogan
  • Lorraine Harper
View graph of relations

BACKGROUND: Intravenous pulse methylprednisolone (MP) is commonly included in the management of severe ANCA associated vasculitis (AAV) despite limited evidence of benefit. We aimed to evaluate outcomes in patients who had, or had not received MP, along with standard therapy for remission induction in severe AAV.

METHODS: We retrospectively studied 114 consecutive patients from five centres in Europe and the United States with a new diagnosis of severe AAV (creatinine > 500 μmol/L or dialysis dependency) and that received standard therapy (plasma exchange, cyclophosphamide and high-dose oral corticosteroids) for remission induction with or without pulse MP between 2000 and 2013. We evaluated survival, renal recovery, relapses, and adverse events over the first 12 months.

RESULTS: Fifty-two patients received pulse MP in addition to standard therapy compared to 62 patients that did not. There was no difference in survival, renal recovery or relapses. Treatment with MP associated with higher risk of infection during the first 3 months (hazard ratio (HR) 2.7, 95%CI [1.4-5.3], p = 0.004) and higher incidence of diabetes (HR 6.33 [1.94-20.63], p = 0.002), after adjustment for confounding factors.

CONCLUSIONS: The results of this study suggest that addition of pulse intravenous MP to standard therapy for remission induction in severe AAV may not confer clinical benefit and may be associated with more episodes of infection and higher incidence of diabetes.

Original languageEnglish
JournalBMC Nephrology
Volume20
Issue number1
Pages (from-to)58
ISSN1471-2369
DOIs
Publication statusPublished - 18 Feb 2019

ID: 58585579